Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization

Abstract

Purpose Fibrovascular scar formation related to subfoveal type 2 choroidal neovascularization (CNV) often causes severe vision loss in eyes with age-related macular degeneration. The authors assessed additional impacts of intravitreal tissue plasminogen activator (tPA), a fibrinolytic compound, combined with intravitreal ranibizumab (IVR) on subfoveal type 2 CNV. Methods Eight eyes of eight patients with type 2 CNV underwent intravitreal injections of ranibizumab and tPA (IVR/tPA) (40 kIU). Twelve eyes of 12 patients with type 2 CNV were treated with only IVR injections, as the control group. For retreatment, IVR was performed as needed. The best-corrected visual acuity (BCVA) and the central retinal thickness (CRT) and macular volume (MV) on optical coherence tomography were recorded periodically for 6 months. Results The subretinal fibrinous and fibrovascular tissue complex regressed or contracted immediately after administration of IVR/tPA in contrast to IVR monotherapy. The total numbers of IVR injections did not differ significantly between the two groups. The mean logarithm of the minimum angle of resolution BCVA in the combination therapy group improved significantly from 0.72 at baseline to 0.51 at month 6 and was superior to that in the monotherapy group (0.70-0.79). The improvements of the mean CRT and MV in the combination therapy group were superior to the monotherapy group. No tPA-related complications developed. Conclusions tPA may have a specific ability to reg…

Overview

Integrity signals

Registry

Crossref · 10.1007/s10384-016-0434-4

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

See all 7

Metadata

Authors
Kachi, I., Yasukawa, T., Kato, A., Takase, N., Morita, H., Kubota, A., Hirano, Y., Uemura, A., & Ogura, Y.
Affiliations
Nagoya City University (JP)
Corresponding author
Yasukawa, Tsutomu
Venue
Japanese Journal of Ophthalmology
Published
2016-02-26
Volume
60
Issue
3
Pages
179-186
ISSN
  • 0021-5155 (ISSN-L)
  • 1613-2246
OpenAlex
W2283167537
Cited by
6
References
25
Citations by year
2024: 1 · 2020: 1 · 2018: 2 · 2017: 1 · 2016: 1
FWCI
1.42
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Japanese Journal of Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • The Research Committee on Chorioretinal Degenerations and Optic Atrophy, The Ministry of Health and Welfare of Japan
  • Grant-in Aid for Scientific Research (C) from the Japan Society for the Promotion of Science and a Grant-in Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan (25462758)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
tissue plasminogen activator, ranibizumab, combination therapy, intravitreal injection, thrombolysis, anti-VEGF therapy, age-related macular degeneration, visual acuity, macular volume, central retinal thickness
MeSH terms
Ranibizumab, Aged, Drug Therapy, Combination, Female, Fibrinolytic Agents, Fovea Centralis, Humans, Male, Tissue Plasminogen Activator, Visual Acuity, Choroidal Neovascularization, Angiogenesis Inhibitors, Tomography, Optical Coherence, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization. https://app.cochat.ai/papers/10.1007/s10384-016-0434-4
The paper
Kachi, I., Yasukawa, T., Kato, A., Takase, N., Morita, H., Kubota, A., Hirano, Y., Uemura, A., & Ogura, Y. (2016). Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-016-0434-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.